Ramos, Azucena
Koch, Catherine E.
Liu-Lupo, Yunpeng
Hellinger, Riley D. http://orcid.org/0000-0001-6303-3641
Kyung, Taeyoon
Abbott, Keene L. http://orcid.org/0000-0002-6166-704X
Fröse, Julia
Goulet, Daniel
Gordon, Khloe S.
Eidell, Keith P.
Leclerc, Paul
Whittaker, Charles A.
Larson, Rebecca C.
Muscato, Audrey J. http://orcid.org/0000-0003-2009-6313
Yates, Kathleen B. http://orcid.org/0000-0002-7383-5573
Dubrot, Juan http://orcid.org/0000-0002-8093-2208
Doench, John G. http://orcid.org/0000-0002-3707-9889
Regev, Aviv
Vander Heiden, Matthew G. http://orcid.org/0000-0002-6702-4192
Maus, Marcela V. http://orcid.org/0000-0002-7578-0393
Manguso, Robert T. http://orcid.org/0000-0003-1336-413X
Birnbaum, Michael E. http://orcid.org/0000-0002-2281-3518
Hemann, Michael T. http://orcid.org/0000-0001-6776-2163
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R21-AI151827)
U.S. Department of Health & Human Services | National Institutes of Health
Article History
Received: 26 September 2023
Accepted: 10 November 2023
First Online: 5 December 2023
Competing interests
: M.V.M. is on the Board of Directors of 2SeventyBio, and holds equity in TCR2, Century Therapeutics, Oncternal, and Neximmune, and has served as a consultant for multiple companies involved in cell therapies. R.T.M. has received consulting or speaking fees from Bristol Myers Squibb, Gilead Sciences and Immunai Therapeutics, has equity ownership in OncoRev, and receives research funding from Calico Life Sciences. M.G.V.H. declares he is an advisory board member for Agios Pharmaceuticals, Aeglea Biotherapeutics, Faeth Therapeutics, Drioa Ventures and iTeos Therapeutics, and a co-founder of Auron Therapeutics. M.E.B. is an equity holder in 3 T Biosciences, and is a co-founder, equity holder, and consultant of Kelonia Therapeutics and Abata Therapeutics. AR is a co-founder and equity holder of Celsius Therapeutics, an equity holder in Immunitas and, until 31 July 2020, was a scientific advisory board member of Thermo Fisher Scientific, Syros Pharmaceuticals, Neogene Therapeutics and Asimov. AR is an employee of Genentech from August 1st, 2020. The remaining authors declare no competing interests.